References
1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA ; 1995:274(13):1049-57.
2. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997:277(22):1775-81.
3. Kang SS, Wong PW, Norusis M. Homocysteinemia due to folate deficiency. Metabolism ; 1987:36(5):458-62.
4. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. Higher total plasma homocysteine in vitamin B deficiency than in heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency. Metabolism ; 1988:37(2):175-8.
5. Ubbink JB, van der Merwe A, Delport R et al. The effect of subnormal vitamin B-12 status on homocysteine metabolism. J Clin Invest ; 1996:98(9):2041-7.
6. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet ; 1991:48(3):536-45.
7. Goyette P, Sumner JS, Milos R et al. Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet ; 1994:7(2):195-200.
8. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet ; 1995:10(1):111-3.
9. Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation ; 1996:93(1):7-9.
10. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala 222 Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost ; 1997:77(5):818-21.
11. Cattaneo M, Tsai MY, Bucciarelli P et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb VascClinical pharmacokinetics. Jpn J Clin Pharmacol Ther, ;   :

Van der Put NM, Steegers-Theunissen RP, Frosst P et al. Mutated methylenetetrahydrofolate reductase is a risk factor for neural tube defects. Q J Med., ;  :

Abbate R, Sardi I, Pepe G et al. The high prevalence of thermolabile methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated with an increased risk for coronary artery disease (CAD). Thromb Haemost, ;  :

Van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation, ;  :

Kang SS, Passen EL, Ruggie N, Wong PW, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation, ;  :

Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocysteine: a possible risk factor for coronary artery disease. J Clin Invest, ;  :

Genest J Jr, Tamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocysteine levels in men with premature coronary artery disease. J Am Coll Cardiol, ;  :

Brattstrom L, Israelsson B, Norrving B et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis, ;  :

Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA, ;  :

Rozen R, Jacques P, Bostom A et al. Interaction of a common mutation in methylenetetrahydrofolate reductase (MTHFR) with low folate status in hyperhomocysteinemia. Am J Human Genet, ;  :A